| __timestamp | Corcept Therapeutics Incorporated | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 882000 | 3243000 |
| Thursday, January 1, 2015 | 1361000 | 2472000 |
| Friday, January 1, 2016 | 2058000 | 2548000 |
| Sunday, January 1, 2017 | 3554000 | 19623000 |
| Monday, January 1, 2018 | 5215000 | 30421000 |
| Tuesday, January 1, 2019 | 5504000 | 32793999 |
| Wednesday, January 1, 2020 | 5582000 | 28304000 |
| Friday, January 1, 2021 | 5281000 | 620000 |
| Saturday, January 1, 2022 | 5385000 | 755000 |
| Sunday, January 1, 2023 | 6481000 | 1322000 |
Igniting the spark of knowledge
In the evolving landscape of biotechnology, understanding cost structures is crucial. From 2014 to 2023, Corcept Therapeutics Incorporated and Viridian Therapeutics, Inc. have shown distinct trajectories in their cost of revenue. Corcept's cost of revenue has steadily increased, peaking at approximately $6.5 million in 2023, marking a 635% rise from 2014. In contrast, Viridian's costs have fluctuated significantly, with a dramatic peak in 2019 at over $32 million, before dropping to around $1.3 million in 2023. This volatility reflects Viridian's strategic shifts and market challenges. The data highlights Corcept's consistent growth strategy, while Viridian's figures suggest a more turbulent path, possibly due to product development cycles or market repositioning. Investors and stakeholders should consider these trends when evaluating the financial health and strategic direction of these companies.
Cost Insights: Breaking Down Merck & Co., Inc. and Viridian Therapeutics, Inc.'s Expenses
Amgen Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Corcept Therapeutics Incorporated
Cost of Revenue Trends: Catalent, Inc. vs Viridian Therapeutics, Inc.
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
Research and Development: Comparing Key Metrics for Corcept Therapeutics Incorporated and Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Evotec SE and Viridian Therapeutics, Inc.